Immix Biopharma (NASDAQ:IMMX - Get Free Report) had its price target boosted by HC Wainwright from $25.00 to $27.00 in a report issued on Monday, Benzinga reports. The brokerage currently has a "buy" rating on the stock. HC Wainwright's price objective would indicate a potential upside of 244.39% from the stock's previous close.
A number of other research analysts have also issued reports on the stock. Mizuho set a $23.00 price target on shares of Immix Biopharma in a research note on Thursday, October 29th. Citigroup reissued a "market outperform" rating on shares of Immix Biopharma in a report on Wednesday, September 30th. Morgan Stanley reissued an "overweight" rating on shares of Immix Biopharma in a research report on Tuesday, October 20th. Weiss Ratings reissued a "sell (d-)" rating on shares of Immix Biopharma in a research report on Thursday, October 15th. Finally, Needham & Company LLC raised their target price on Immix Biopharma from $21.00 to $30.00 and gave the stock a "buy" rating in a research note on Tuesday, September 29th. Eight analysts have rated the stock with a Buy rating and one has given a Sell rating to the company's stock. According to MarketBeat.com, the stock presently has an average rating of "Moderate Buy" and an average target price of $24.14.
View Our Latest Stock Analysis on Immix Biopharma
Immix Biopharma Price Performance
Shares of IMMX opened at $7.84 on Monday. The company has a market cap of $560.87 million, a price-to-earnings ratio of -9.45 and a beta of 0.29. Immix Biopharma has a twelve month low of $3.56 and a twelve month high of $15.10. The company has a 50 day moving average of $9.82 and a two-hundred day moving average of $9.58.
Immix Biopharma (NASDAQ:IMMX - Get Free Report) last announced its earnings results on Thursday, November 12th. The company reported ($0.19) earnings per share (EPS) for the quarter, meeting the consensus estimate of ($0.19). On average, sell-side analysts expect that Immix Biopharma will post -0.76 EPS for the current year.
Hedge Funds Weigh In On Immix Biopharma
Institutional investors have recently modified their holdings of the stock. Blue Owl Capital Holdings LP purchased a new stake in shares of Immix Biopharma in the second quarter valued at approximately $4,511,000. Bank of America Corp DE acquired a new position in shares of Immix Biopharma during the 2nd quarter worth approximately $4,260,000. Wellington Management Group LLP acquired a new position in shares of Immix Biopharma during the 2nd quarter worth approximately $15,191,000. Tocqueville Asset Management L.P. purchased a new position in shares of Immix Biopharma during the 2nd quarter valued at approximately $913,000. Finally, Velan Capital Investment Management LP lifted its position in shares of Immix Biopharma by 46.6% during the 2nd quarter. Velan Capital Investment Management LP now owns 1,085,000 shares of the company's stock valued at $11,186,000 after buying an additional 345,000 shares in the last quarter. Hedge funds and other institutional investors own 11.26% of the company's stock.
About Immix Biopharma
(
Get Free Report)
Immix Biopharma is a clinical-stage biopharmaceutical company developing cell therapies for serious diseases, with a focus on relapsed or refractory AL amyloidosis, a rare condition in which abnormal proteins build up in organs and tissues. The company's lead candidate, NXC-201, is an investigational CAR T-cell therapy designed to target BCMA, a protein found on certain plasma cells. It is being studied in clinical trials and has not been approved for commercial use. Immix Biopharma is based in the United States and is led by Chief Executive Officer Ilya Rachman.
Featured Stories

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Immix Biopharma, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Immix Biopharma wasn't on the list.
While Immix Biopharma currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Looking for higher dividend income in 2027? Discover seven high-yield dividend stocks with attractive payouts, proven dividend histories and growth potential.
Get This Free Report
Continue following MarketBeat
Add MarketBeat as your preferred source on Google to see our latest stories in your feed.
Like this article? Share it with a colleague.
Link copied to clipboard.